Metabolites of Purine Nucleoside Phosphorylase (NP) in Serum Have the Potential to Delineate Pancreatic Adenocarcinoma
AuthorsVareed, Shaiju K.
Bhat, Vadiraja B.
Vasu, Vihas T.
Creighton, Chad J.
Thangjam, Gagan Singh
Giri, Judith G.
Nesvizhskii, Alexey I.
Asea, Alexander A. A.
Cashikar, Anil G.
MetadataShow full item record
AbstractPancreatic Adenocarcinoma (PDAC), the fourth highest cause of cancer related deaths in the United States, has the most aggressive presentation resulting in a very short median survival time for the affected patients. Early detection of PDAC is confounded by lack of specific markers that has motivated the use of high throughput molecular approaches to delineate potential biomarkers. To pursue identification of a distinct marker, this study profiled the secretory proteome in 16 PDAC, 2 carcinoma in situ (CIS) and 7 benign patients using label-free mass spectrometry coupled to 1D-SDS-PAGE and Strong Cation-Exchange Chromatography (SCX). A total of 431 proteins were detected of which 56 were found to be significantly elevated in PDAC. Included in this differential set were Parkinson disease autosomal recessive, early onset 7 (PARK 7) and Alpha Synuclein (aSyn), both of which are known to be pathognomonic to Parkinson's disease as well as metabolic enzymes like Purine Nucleoside Phosphorylase (NP) which has been exploited as therapeutic target in cancers. Tissue Microarray analysis confirmed higher expression of aSyn and NP in ductal epithelia of pancreatic tumors compared to benign ducts. Furthermore, extent of both aSyn and NP staining positively correlated with tumor stage and perineural invasion while their intensity of staining correlated with the existence of metastatic lesions in the PDAC tissues. From the biomarker perspective, NP protein levels were higher in PDAC sera and furthermore serum levels of its downstream metabolites guanosine and adenosine were able to distinguish PDAC from benign in an unsupervised hierarchical classification model. Overall, this study for the first time describes elevated levels of aSyn in PDAC as well as highlights the potential of evaluating NP protein expression and levels of its downstream metabolites to develop a multiplex panel for non-invasive detection of PDAC.
CitationPLoS One. 2011 Mar 23; 6(3):e17177
- Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma.
- Authors: LaConti JJ, Laiakis EC, Mays AD, Peran I, Kim SE, Shay JW, Riegel AT, Fornace AJ Jr, Wellstein A
- Issue date: 2015
- Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
- Authors: Makawita S, Dimitromanolakis A, Soosaipillai A, Soleas I, Chan A, Gallinger S, Haun RS, Blasutig IM, Diamandis EP
- Issue date: 2013 Sep 3
- Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma.
- Authors: Hwang TL, Liang Y, Chien KY, Yu JS
- Issue date: 2006 Apr
- Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas.
- Authors: Qi T, Han J, Cui Y, Zong M, Liu X, Zhu B
- Issue date: 2008 Jan
- Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.
- Authors: Chang DZ, Ma Y, Ji B, Liu Y, Hwu P, Abbruzzese JL, Logsdon C, Wang H
- Issue date: 2012 Apr 4